[{"id":"d5eefa5d-70d4-45bb-8c5e-7f0838c3242d","acronym":"REPARP","url":"https://clinicaltrials.gov/study/NCT05378204","created_at":"2022-05-18T13:00:40.492Z","updated_at":"2024-07-02T16:35:17.213Z","phase":"","brief_title":"Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.","source_id_and_acronym":"NCT05378204 - REPARP","lead_sponsor":"Institut Claudius Regaud","biomarkers":" HER-2 • BRCA1 • BRCA • TP53BP1","pipe":" | ","alterations":" BRCA2 mutation • HR positive • HER-2 amplification • HER-2 negative • BRCA mutation","tags":["HER-2 • BRCA1 • BRCA • TP53BP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • HR positive • HER-2 amplification • HER-2 negative • BRCA mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 06/23/2022","start_date":" 06/23/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-02-28"},{"id":"0ae73cff-61c0-41a6-852a-74840ce5f7a8","acronym":"Radio-Marker","url":"https://clinicaltrials.gov/study/NCT05513469","created_at":"2022-08-24T21:07:36.463Z","updated_at":"2024-07-02T16:35:51.102Z","phase":"","brief_title":"Biomarker Identification of Radionuclide Therapy-induced Radiation Responses","source_id_and_acronym":"NCT05513469 - Radio-Marker","lead_sponsor":"Erasmus Medical Center","biomarkers":" TP53BP1","pipe":"","alterations":" ","tags":["TP53BP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-04-07"},{"id":"419a98b5-d2bf-415b-9307-4fc2b382b434","acronym":"TOMAS","url":"https://clinicaltrials.gov/study/NCT02398058","created_at":"2021-04-14T18:53:45.928Z","updated_at":"2025-02-25T15:06:31.322Z","phase":"Phase 1","brief_title":"Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)","source_id_and_acronym":"NCT02398058 - TOMAS","lead_sponsor":"Italian Sarcoma Group","biomarkers":" BRCA1 • ERCC1 • ERCC2 • PARP1 • TP53BP1","pipe":"","alterations":" ","tags":["BRCA1 • ERCC1 • ERCC2 • PARP1 • TP53BP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Yondelis (trabectedin)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 07/20/2014","start_date":" 07/20/2014","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2021-04-14"}]